Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Relationship Between Rates of ElevatedLiver Enzymes and % LDL-C Reduction
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Relationship Between Rates ofRhabdomyolysis and % LDL-C Reduction
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Rate of Elevated LiverEnzymes by Statin Dose Category
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Rate of Elevated LiverEnzymes by Lovastatin Dose Category
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Rate of Elevated LiverEnzymes by Simvastatin Dose Category
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Rate of Elevated LiverEnzymes by Atorvastatin Dose Category
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Characteristics of Large Prospective Randomized Controlled Statin Trials in Which Incident Cancer Rates Were
Reported, and Used for the Present Analysis
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and % LDL-C
Reduction
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and Absolute LDL-C
Reduct
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and Achieved LDL-C
Level
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
Rate of Newly DiagnosedCancer by Statin Dose Category
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18
References
Alawi A. Alsheikh-Ali, et al. JACC 2007;50:409-18